Xoma, a biopharmaceutical company, and Takeda Pharmaceutical Company have expanded their existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of R&D technologies and integrated information and data management systems.
Xoma will receive a $29 million expansion fee and may receive potential milestones and royalties on antibody products. Xoma may incur an estimated $7.5 million for taxes and other costs related to the expanded collaboration.
Xoma and Takeda have previously initiated a collaboration in which Xoma is using its extensive collection of antibody phage display libraries and antibody optimization technologies to discover therapeutic antibodies in multiple therapeutic areas. Xoma activities may also include preclinical studies to support regulatory filings, cell line and process development, and production of antibodies for initial clinical trials.
Takeda will be responsible for clinical trials and commercialization of drugs after investigational new drug submission, and has manufacturing rights once a product enters into Phase II clinical trials.
Shigenori Ohkawa, general manager of pharmaceutical research division at Takeda, said: This collaboration expansion is intended to help accelerate Takeda’s corporate goal of building a highly competitive antibody product pipeline by augmenting its already significant in-house capabilities located in San Francisco and Osaka. With the antibody technologies of Xoma, we will further complement our antibody research activities for the creation of new drugs.